talfirastide
Trials 31 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01543971 Comparator | Dec 2009 | — | Tarix Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04605887 Comparator | Jan 2021 → Nov 2023 | COVID-19 | Rambam Health Care Campus | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04375124 Comparator | Apr → Aug 2020 | COVID-19 | Kanuni Sultan Suleyman Training and Research Hospital | Completed | No outcome recorded |
Evidence & citations 22 cited values
Every value below carries the sentence it was read from. 38 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | talfirastide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06135103 ↗ |
| Known as | 5-ile-angiotensin-(1-7) | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545347 ↗ |
| Known as | A(1-7) | “USB002 is pharmaceutically formulated Angiotensin 1-7 \[A(1-7)\], a non-hypertensive derivative of Angiotensin-II (A-II), and is suspended in a vehicle as a sterile solution of USB002.” NCT04778059 ↗1“TXA127 is pharmaceutically formulated Angiotensin 1-7 \[A(1-7)\]” NCT01554254 ↗ |
| Known as | Ang-(1-7) | “Angiotensin-(1-7) [Ang-(1-7)] is an endogenous peptide hormone of the renin-angiotensin system with antiproliferative and antiangiogenic properties.” PMID 19920106 ↗ Nov 20092“A substance, Angiotensin-(1-7) \[Ang-(1-7)\], is known to decrease inflammation in the brain.” NCT05336175 ↗ “Angiotensin 1-7 (Ang-(1-7))” NCT03252093 ↗ |
| Known as | Angiotensin 1-7 | “Single-arm safety/efficacy trial of TXA127 (Angiotensin 1-7) in subjects undergoing allogeneic peripheral blood stem cell transplantation for the treatment of a variety of...” NCT01882387 ↗27“USB002 is pharmaceutically formulated Angiotensin 1-7 \[A(1-7)\], a non-hypertensive derivative of Angiotensin-II (A-II), and is suspended in a vehicle as a sterile solution of USB002.” NCT04778059 ↗ “Single-arm safety/efficacy trial of TXA127 (Angiotensin 1-7) in subjects undergoing double cord blood transplantation for the treatment of hematologic malignancies.” NCT01882374 ↗ “Angiotensin-(1-7) is a peptide that is downregulated in COVID-19 patient and it may potentially improve respiratory function in this setting.” NCT04332666 ↗ “TXA127 is pharmaceutically-formulated angiotensin 1-7, a non-hypertensive derivative of angiotensin II” NCT01300611 ↗ “A substance, Angiotensin-(1-7) \[Ang-(1-7)\], is known to decrease inflammation in the brain.” NCT05336175 ↗ “Randomized Controlled Trial of Angiotensin 1-7 (TXA127) for the Treatment of Severe COVID-19” NCT04401423 ↗ “TXA127 is pharmaceutically formulated Angiotensin 1-7 \[A(1-7)\]” NCT01554254 ↗ “Angiotensin 1-7 (Ang-(1-7))” NCT03252093 ↗ |
| Known as | Angiotensin fragment 1-7 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545347 ↗ |
| Known as | Angiotensin peptide (1-7) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04375124 ↗ |
| Known as | Asp-arg-val-tyr-ile-his-pro | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545347 ↗ |
| Known as | Bf-angiotensin 1-7 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545347 ↗ |
| Known as | ETRX-101 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545347 ↗ |
| Known as | Human angiotensin ii (1-7) | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545347 ↗ |
| Known as | Marstem | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545347 ↗ |
| Known as | Sh-heptapeptide-13 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545347 ↗ |
| Known as | Talfirastida | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545347 ↗ |
| Known as | TXA-127 | “2 investigational RAS agents, TXA-127 (synthetic angiotensin [1-7]) and TRV-027 (an angiotensin II type 1 receptor-biased ligand)” PMID 37039791 ↗ Apr 202312“A randomized, placebo-controlled, double-blinded pilot study of angiotensin 1-7 (TXA-127) for the treatment of severe COVID-19.” PMID 35902867 ↗ Jul 2022 “talfirastide (TXA127)” NCT06135103 ↗ |
| Known as | USB-003 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545347 ↗ |
| Known as | USB002 | “USB002 is pharmaceutically formulated Angiotensin 1-7 \[A(1-7)\], a non-hypertensive derivative of Angiotensin-II (A-II), and is suspended in a vehicle as a sterile solution of USB002.” NCT04778059 ↗ |
| Action | Activate | “Proto-oncogene Mas agonist” CHEMBL3545347 ↗ |
| Action | Restore | “Angiotensin-(1-7) is a beneficial hormone that is reduced in obesity and restoration of this hormone improves endothelial function” NCT03604289 ↗ |
| Modality | Peptide | “Angiotensin-(1-7) [Ang-(1-7)] is an endogenous peptide hormone of the renin-angiotensin system with antiproliferative and antiangiogenic properties.” PMID 19920106 ↗ Nov 2009 |
| Route | Subcutaneous | “Patients receive therapeutic angiotensin-(1-7) subcutaneously on days 1-5.” NCT00471562 ↗ |
| Target | MAS1 | “Proto-oncogene Mas agonist” CHEMBL3545347 ↗ |